Navigation Links
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Date:6/7/2008

therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products visit, http://www.lillydiabetes.com.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

This press release contains forward-looking statements about Amylin and Lilly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYETTA and the revenues generated from BYETTA may be affected by competition; unexpected new data; technical issue; clinical trials not confirming previous results; pre-clinical trials not predicting future results; label expansion requests, including the FDA submission referred to in this press release, not being submitted in a timely manner or receiving regulatory approval; or manufacturing and supply issues. The potential for BYETTA may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the commercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin and Lilly's most recently filed SEC including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. A
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
5. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
9. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/dg23tb/global ) has announced ... 2015-2019" report to their offering. The ... of 5.9% over the period 2014-2019. One ... rise in demand for vials and ampules. The Parenteral ... among all the segments at a CAGR of 8.83 ...
(Date:6/3/2015)... DALLAS , June 3, 2015 ... report "Interventional Cardiology & Peripheral Vascular Devices Market ... Angiography Catheters, EVAR Stent Grafts, IVC Filters, Stents, ... by MarketsandMarkets, the Interventional Cardiology and Peripheral Vascular ... Billion by 2019 with a CAGR of 7.4% ...
(Date:6/3/2015)... 2015  VA North Texas Health Care System ... vBloc, a technology-based, scientifically advanced weight loss therapy.  ... called the Maestro® Rechargeable System that intermittently blocks ... involving food intake and processing between the brain ... customizable to meet the needs of a patient,s ...
Breaking Medicine Technology:Global Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, Gerresheimer, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3
... NANTONG CITY, China, Oct. 8 /PRNewswire-Asia-FirstCall/ ... (the "Company") is pleased to announce that the Company ... as a pharmaceutical raw material (Certificate #2009S01805) from the ... Gabexate Mesylate is a serine ...
... FRANKLIN LAKES, N.J., Oct. 7 BD (Becton, Dickinson and ... company, today announced that it is pleased to have been ... Rankings" of the 500 largest U.S. corporations based on environmental ... sector and 83rd overall. , Additionally, BD has been ...
Cached Medicine Technology:Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material 2BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes 2
(Date:6/3/2015)... 03, 2015 Alberto Grignolo, PhD, will ... upcoming Annual Meeting. DIA’s Global Inspire Award program recognizes ... excellence, and commitment to service on a global scale. ... Award that annually recognizes one DIA member for meritorious ... mission of DIA to foster innovation to improve health ...
(Date:6/3/2015)... Washington, DC (PRWEB) June 03, 2015 ... Global Inspire Award at DIA’s upcoming Annual Meeting. DIA’s ... for their leadership, level of excellence, and commitment to ... will receive the President’s Award for Outstanding Contribution to ... and innovative contributions to advancing global health. ...
(Date:6/3/2015)... Researchers at the University of Western ... say the tried-and-true marker mesothelin is the best option ... the research. Click here to read it now. ... Asbestos Related Diseases say, even though a mesothelin test ... preferable to fibulin-3 for identifying mesothelioma. , “Preliminary ...
(Date:6/3/2015)... June 03, 2015 On Sunday, June ... world will gather in their local communities to observe ... cities across the U.S. and abroad will hold celebrations ... attention to the ongoing challenges of cancer survivorship, and ... diagnosis can be fruitful, rewarding, and inspiring.,  , National ...
(Date:6/3/2015)... are challenging and unpredictable times for traditional organizations across ... are rewriting the rules for business as we knew ... businesses to take on a more agile approach in ... On top of this there is a growing trend ... new innovation and approaches to business. , The manager ...
Breaking Medicine News(10 mins):Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3Health News:Co-discoverer of Ebola Virus and AIDS Pioneer to be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Co-discoverer of Ebola Virus and AIDS Pioneer to be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2
... Consuming two or more soft drinks per week increased ... compared with individuals who did not consume soft drinks, ... & Prevention , a journal of the American Association ... cancer remains one of the most deadly; only 5 ...
... born prematurely in the US, according to data presented ... findings were reported at the 30th Annual Meeting of ... were published in the latest issue of the ... reported that CP is associated with inflammation of the ...
... research that improves patient safety and surgical outcomes with ... WHO Surgical Safety Checklist was created as a tool ... "With this award AcademyHealth recognizes research that ... care system better," said AcademyHealth President W. David Helms, ...
... TALLAHASSEE, Fla. , Feb. 9 LearnSomething ... drug and mass retailers, today announced that Phil Keough ... company, has joined LearnSomething,s senior management as Chief Business Development ... to continue developing and distributing innovative compliance, operational and sales ...
... The incidence of advanced breast cancer diagnosis among black ... to white women between 1992 and 2004, according to ... Center. In addition, the disparity in the incidence of ... as rates fell among whites but increased slightly among ...
... childhood obesity is directly related to children,s exposure to commercials ... of Public Health study published in the American Journal ... J. Zimmerman and Janice F. Bell, is the first to ... determine whether different kinds of content may exert different effects ...
Cached Medicine News:Health News:Soft drinks may increase risk of pancreatic cancer 2Health News:Incidence of cerebral palsy on rise in US 2Health News:2010 HSR Impact Award recognizes surgical safety research 2Health News:LearnSomething Brings Phil Keough On Board to Spearhead Retail Products and Services 2Health News:LearnSomething Brings Phil Keough On Board to Spearhead Retail Products and Services 3Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 2Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 3Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 4Health News:Childhood obesity: It's not the amount of TV, it's the number of junk food commercials 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: